Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
<p>Abstract</p> <p>Background</p> <p>Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, n...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-10-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-2407/12/482 |
| _version_ | 1818148166705348608 |
|---|---|
| author | Fabi Alessandra Russillo Michelangelo Ferretti Gianluigi Metro Giulio Nisticò Cecilia Papaldo Paola De Vita Ferdinando D’Auria Giuliana Vidiri Antonello Giannarelli Diana Cognetti Francesco |
| author_facet | Fabi Alessandra Russillo Michelangelo Ferretti Gianluigi Metro Giulio Nisticò Cecilia Papaldo Paola De Vita Ferdinando D’Auria Giuliana Vidiri Antonello Giannarelli Diana Cognetti Francesco |
| author_sort | Fabi Alessandra |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no clinical data exist about combination of maintenance Bevacizumab (mBev) with HT.</p> <p>Methods</p> <p>Thirty-five patients who experienced a response after first-line BT, were given mBev at the dose of 15 mg/kg every 3 weeks. Among 30 pts with hormonal receptor-positive metastatic breast cancer (MBC), 20 (66.6%) received HT with mBev (mHTBev). Objective of the study was the outcome and safety of mBev and in two groups of patients receiving HT or not.</p> <p>Results</p> <p>Complete response and partial response was achieved/maintained in 4 (11.4%) and 13 (37.1%) patients, respectively (overall response rate: 48.5%). Clinical benefit was obtained on 23 patients (65.7%). Median of mBev PFS and clinical benefit were 6.8 months (95% CI: 0.8-12.7) and 17.1 months (95% CI :12.2-21.9), respectively. Median PFS of patients who received mHTBev was longer than mBev without HT (13 months and 4.1 months, respectively, p = 0.05). The most common severe toxicities were proteinuria (11.4%) and hypertension (8.5%). No additional toxicity was observed with HTBev.</p> <p>Conclusion</p> <p>Maintenance bevacizumab with or without anti-hormonal therapy in patients with hormone receptor positive breast cancer is tolerable and associated with long-term clinical outcome; these results encourage the strategy of prolonging bevacizumab until progression in combination with anti-hormonal agents.</p> |
| first_indexed | 2024-12-11T12:46:49Z |
| format | Article |
| id | doaj.art-7c90707cb1a14714928c369ae027b750 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-11T12:46:49Z |
| publishDate | 2012-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-7c90707cb1a14714928c369ae027b7502022-12-22T01:06:48ZengBMCBMC Cancer1471-24072012-10-0112148210.1186/1471-2407-12-482Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapyFabi AlessandraRussillo MichelangeloFerretti GianluigiMetro GiulioNisticò CeciliaPapaldo PaolaDe Vita FerdinandoD’Auria GiulianaVidiri AntonelloGiannarelli DianaCognetti Francesco<p>Abstract</p> <p>Background</p> <p>Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no clinical data exist about combination of maintenance Bevacizumab (mBev) with HT.</p> <p>Methods</p> <p>Thirty-five patients who experienced a response after first-line BT, were given mBev at the dose of 15 mg/kg every 3 weeks. Among 30 pts with hormonal receptor-positive metastatic breast cancer (MBC), 20 (66.6%) received HT with mBev (mHTBev). Objective of the study was the outcome and safety of mBev and in two groups of patients receiving HT or not.</p> <p>Results</p> <p>Complete response and partial response was achieved/maintained in 4 (11.4%) and 13 (37.1%) patients, respectively (overall response rate: 48.5%). Clinical benefit was obtained on 23 patients (65.7%). Median of mBev PFS and clinical benefit were 6.8 months (95% CI: 0.8-12.7) and 17.1 months (95% CI :12.2-21.9), respectively. Median PFS of patients who received mHTBev was longer than mBev without HT (13 months and 4.1 months, respectively, p = 0.05). The most common severe toxicities were proteinuria (11.4%) and hypertension (8.5%). No additional toxicity was observed with HTBev.</p> <p>Conclusion</p> <p>Maintenance bevacizumab with or without anti-hormonal therapy in patients with hormone receptor positive breast cancer is tolerable and associated with long-term clinical outcome; these results encourage the strategy of prolonging bevacizumab until progression in combination with anti-hormonal agents.</p>http://www.biomedcentral.com/1471-2407/12/482Maintenance BevacizumabAntiangiogenic agentsHER2 negative metastatic breast cancer |
| spellingShingle | Fabi Alessandra Russillo Michelangelo Ferretti Gianluigi Metro Giulio Nisticò Cecilia Papaldo Paola De Vita Ferdinando D’Auria Giuliana Vidiri Antonello Giannarelli Diana Cognetti Francesco Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy BMC Cancer Maintenance Bevacizumab Antiangiogenic agents HER2 negative metastatic breast cancer |
| title | Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy |
| title_full | Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy |
| title_fullStr | Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy |
| title_full_unstemmed | Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy |
| title_short | Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy |
| title_sort | maintenance bevacizumab beyond first line paclitaxel plus bevacizumab in patients with her2 negative hormone receptor positive metastatic breast cancer efficacy in combination with hormonal therapy |
| topic | Maintenance Bevacizumab Antiangiogenic agents HER2 negative metastatic breast cancer |
| url | http://www.biomedcentral.com/1471-2407/12/482 |
| work_keys_str_mv | AT fabialessandra maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy AT russillomichelangelo maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy AT ferrettigianluigi maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy AT metrogiulio maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy AT nisticocecilia maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy AT papaldopaola maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy AT devitaferdinando maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy AT dauriagiuliana maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy AT vidiriantonello maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy AT giannarellidiana maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy AT cognettifrancesco maintenancebevacizumabbeyondfirstlinepaclitaxelplusbevacizumabinpatientswithher2negativehormonereceptorpositivemetastaticbreastcancerefficacyincombinationwithhormonaltherapy |